EP0770058A1 - Neue chemische verbindung, ihre herstellung und ihre verwendung als arzneistoff - Google Patents
Neue chemische verbindung, ihre herstellung und ihre verwendung als arzneistoffInfo
- Publication number
- EP0770058A1 EP0770058A1 EP95922492A EP95922492A EP0770058A1 EP 0770058 A1 EP0770058 A1 EP 0770058A1 EP 95922492 A EP95922492 A EP 95922492A EP 95922492 A EP95922492 A EP 95922492A EP 0770058 A1 EP0770058 A1 EP 0770058A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- formula
- treatment
- diseases
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the invention relates to the compound of the formula
- Chronic obstructive pulmonary diseases such as chronic bronchitis, psoriasis, colitis uicerosa, gastro- or enteropathy induced by non-steroidal anti-inflammatory drugs, Alzheimer's disease, shock, reperfusion damage / ischemia, atherosclerosis, multiple sclerosis.
- the new compound can also be used to treat diseases or conditions in which the passage of cells from the blood via the vascular endothelium into the tissue is important (for example metastasis) or diseases and conditions in which the combination of LTB4 or another molecule (for example 12-HETE) with the LTB4 receptor has an influence on cell proliferation (e.g. chronic myelocytic leukemia).
- diseases or conditions in which the passage of cells from the blood via the vascular endothelium into the tissue is important for example metastasis
- diseases and conditions in which the combination of LTB4 or another molecule (for example 12-HETE) with the LTB4 receptor has an influence on cell proliferation e.g. chronic myelocytic leukemia.
- the new compound can also be used in combination with other active ingredients, such as those used for the same indications, or e.g. with antiallergics, secretolytics, ß2-adrenergics, inhalable steroids, antihistamines and / or PAF antagonists.
- Administration can be topical, oral, transdermal, nasal, parenteral or inhalative.
- the therapeutic or prophylactic dose depends on the patient's body weight and the nature and seriousness of the disease. When used orally, the dose is between 10 and 500 mg, preferably between 20 and 250 mg. When used by inhalation, the patient is given between about 0.5 and 25, in particular between 2 and 20, mg of active ingredient.
- the new compounds can be administered in customary preparations, for example as tablets, dragées, capsules, wafers, powders, granules, solutions, emulsions, syrups, inhalation aerosols, ointments, suppositories.
- Active ingredient according to the invention 20 parts by weight
- the ingredients are processed in the usual way to tablets of 500 mg weight. If desired, the active substance content can be increased or decreased and the amount of glucose reduced or increased accordingly. Suppositories
- composition active ingredient according to the invention 100 parts by weight of lactose, powdered 45 parts by weight of cocoa butter 1555 parts by weight
- the ingredients are processed in the usual way to form suppositories weighing 1.7 g.
- Micronized active ingredient powder (compound of formula I; particle size approx. 0.5 to 7 ⁇ m) is filled into hard gelatin capsules in an amount of 5 mg, optionally with the addition of micronized lactose.
- the powder is extracted from conventional inhalation devices, e.g. according to DE-A 3 345 722, inhaled.
- the new compound shows a surprisingly superior activity compared to the known LTB4 antagonists. This is expressed, for example, in the test result for the LTB4-induced neutrophil accumulation on the mouse ear.
- the ED50 value of 0.05 mg / kg obtained is far lower than the values found for structurally similar compounds
- the new connection can be established using standard methods:
- reaction is conveniently carried out in a polar solvent such as
- Ethanol, glacial acetic acid or dimethylformamide at room temperature up to 60 ° C and at normal pressure up to 5 bar.
- Raney nickel or platinum are used as catalysts.
- the amidoxime used as the starting material is obtained, for example, by reacting the corresponding nitrile with hydroxylamine.
- Compound I can also be produced from partial structures with an amidine group already present.
- a compound of formula III is reacted with the phenol of formula IV or the phenol of formula V with a compound of formula VI:
- the alkyl radicals R2 are generally those radicals having up to 6 carbon atoms. Phenyl or tolyl is preferably used as the aryl.
- the methanol is distilled off, the residue is taken up in 2000 ml of ethyl acetate and extracted twice with 500 ml of water each time.
- the ethyl acetate is distilled off and the residue is recrystallized from 300 ml of ethanol.
- the product is dissolved hot in 200 ml of ethanol and slowly cooled to room temperature overnight.
- the crystals are filtered off, washed with 50 ml of cold ethanol and dried. Yield: 69 g; Melting point 160 ° C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4424714A DE4424714A1 (de) | 1994-07-13 | 1994-07-13 | Neue chemische Verbindung, ihre Herstellung und ihre Verwendung als Arnzneistoff |
DE4424714 | 1994-07-13 | ||
PCT/EP1995/002113 WO1996002496A1 (de) | 1994-07-13 | 1995-06-03 | Neue chemische verbindung, ihre herstellung und ihre verwendung als arzneistoff |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0770058A1 true EP0770058A1 (de) | 1997-05-02 |
Family
ID=6523048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95922492A Withdrawn EP0770058A1 (de) | 1994-07-13 | 1995-06-03 | Neue chemische verbindung, ihre herstellung und ihre verwendung als arzneistoff |
Country Status (25)
Country | Link |
---|---|
US (1) | US5686496A (xx) |
EP (1) | EP0770058A1 (xx) |
JP (1) | JPH10502646A (xx) |
KR (1) | KR970704674A (xx) |
CN (1) | CN1152303A (xx) |
AU (1) | AU2736895A (xx) |
BG (1) | BG101104A (xx) |
BR (1) | BR9508395A (xx) |
CA (1) | CA2194886A1 (xx) |
CO (1) | CO4410185A1 (xx) |
CZ (1) | CZ8297A3 (xx) |
DE (1) | DE4424714A1 (xx) |
EE (1) | EE9700065A (xx) |
FI (1) | FI970095A0 (xx) |
HR (1) | HRP950363A2 (xx) |
HU (1) | HUT76827A (xx) |
IL (1) | IL114572A0 (xx) |
MX (1) | MX9700245A (xx) |
NO (1) | NO970123L (xx) |
PE (1) | PE35196A1 (xx) |
PL (1) | PL318114A1 (xx) |
SK (1) | SK1897A3 (xx) |
WO (1) | WO1996002496A1 (xx) |
YU (1) | YU45395A (xx) |
ZA (1) | ZA955781B (xx) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486181B1 (en) | 1992-08-28 | 2002-11-26 | City Of Hope | Human leukocutye 12-lipoxygenase and its role in the pathogenesis of disease states |
US6191169B1 (en) | 1992-08-28 | 2001-02-20 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
EP0743064A1 (en) * | 1995-05-17 | 1996-11-20 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease |
DE19546452A1 (de) * | 1995-12-13 | 1997-06-19 | Boehringer Ingelheim Kg | Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel |
DE19636689A1 (de) * | 1996-09-10 | 1998-03-12 | Boehringer Ingelheim Kg | Neue Benzamidinderivate |
DE19718334A1 (de) | 1997-04-30 | 1998-11-05 | Boehringer Ingelheim Pharma | Neue Benzylaminderivate und Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
ID24720A (id) | 1997-12-12 | 2000-08-03 | Novartis Ag | Senyawa amidino tersubstitusi dalam perawatan penyakit gangguan paru-paru kronis |
DE19834713A1 (de) * | 1998-07-31 | 2000-02-03 | Boehringer Ingelheim Pharma | Neue Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US6528491B2 (en) * | 2000-10-24 | 2003-03-04 | Boehringer Ingelheim Pharma Kg | Pyranoside derivatives |
JP2004523512A (ja) * | 2001-01-16 | 2004-08-05 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ムチン遺伝子の増大された発現により生じる疾患の治療及び/又は予防のためのltb4アンタゴニストの使用 |
BR0212078A (pt) * | 2001-08-31 | 2004-09-28 | Neurochem Int Ltd | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto |
US20070105104A1 (en) * | 2003-05-06 | 2007-05-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4) |
US7262223B2 (en) * | 2004-01-23 | 2007-08-28 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
US20080200526A1 (en) * | 2004-07-05 | 2008-08-21 | Jin Soo Lee | Composition for the Prevention and Treatment of Allergic Inflammatory Disease |
EP1765333A4 (en) * | 2004-07-14 | 2008-06-18 | Inflammation Res Ct Company Lt | PROCESS FOR INHIBITING TUMOR METASTASES |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0518818A3 (en) * | 1991-06-11 | 1993-04-28 | Ciba-Geigy Ag | Arylethers, their manufacture and use as medicament |
CZ287209B6 (en) * | 1992-02-05 | 2000-10-11 | Boehringer Ingelheim Kg | Amidine derivatives, process of their preparation and pharmaceutical preparations containing thereof |
-
1994
- 1994-07-13 DE DE4424714A patent/DE4424714A1/de not_active Withdrawn
-
1995
- 1995-06-03 MX MX9700245A patent/MX9700245A/es unknown
- 1995-06-03 PL PL95318114A patent/PL318114A1/xx unknown
- 1995-06-03 HU HU9700060A patent/HUT76827A/hu unknown
- 1995-06-03 JP JP8504619A patent/JPH10502646A/ja active Pending
- 1995-06-03 KR KR1019970700123A patent/KR970704674A/ko not_active Application Discontinuation
- 1995-06-03 CN CN95194047A patent/CN1152303A/zh active Pending
- 1995-06-03 CZ CZ9782A patent/CZ8297A3/cs unknown
- 1995-06-03 WO PCT/EP1995/002113 patent/WO1996002496A1/de not_active Application Discontinuation
- 1995-06-03 AU AU27368/95A patent/AU2736895A/en not_active Abandoned
- 1995-06-03 CA CA002194886A patent/CA2194886A1/en not_active Abandoned
- 1995-06-03 EE EE9700065A patent/EE9700065A/xx unknown
- 1995-06-03 SK SK18-97A patent/SK1897A3/sk unknown
- 1995-06-03 BR BR9508395A patent/BR9508395A/pt unknown
- 1995-06-03 US US08/765,527 patent/US5686496A/en not_active Expired - Fee Related
- 1995-06-03 EP EP95922492A patent/EP0770058A1/de not_active Withdrawn
- 1995-06-27 HR HRP4424714.1A patent/HRP950363A2/xx not_active Application Discontinuation
- 1995-07-06 YU YU45395A patent/YU45395A/sh unknown
- 1995-07-11 PE PE1995273520A patent/PE35196A1/es not_active Application Discontinuation
- 1995-07-12 IL IL11457295A patent/IL114572A0/xx unknown
- 1995-07-12 CO CO95030620A patent/CO4410185A1/es unknown
- 1995-07-12 ZA ZA955781A patent/ZA955781B/xx unknown
-
1997
- 1997-01-04 BG BG101104A patent/BG101104A/xx unknown
- 1997-01-10 FI FI970095A patent/FI970095A0/fi not_active Application Discontinuation
- 1997-01-10 NO NO970123A patent/NO970123L/no unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9602496A1 * |
Also Published As
Publication number | Publication date |
---|---|
HRP950363A2 (en) | 1997-08-31 |
CA2194886A1 (en) | 1996-02-01 |
ZA955781B (en) | 1996-02-22 |
WO1996002496A1 (de) | 1996-02-01 |
HU9700060D0 (en) | 1997-02-28 |
PL318114A1 (en) | 1997-05-12 |
JPH10502646A (ja) | 1998-03-10 |
US5686496A (en) | 1997-11-11 |
SK1897A3 (en) | 1997-08-06 |
PE35196A1 (es) | 1996-09-05 |
YU45395A (sh) | 1997-12-05 |
FI970095A (fi) | 1997-01-10 |
BG101104A (en) | 1998-04-30 |
EE9700065A (et) | 1997-08-15 |
IL114572A0 (en) | 1995-11-27 |
NO970123D0 (no) | 1997-01-10 |
NO970123L (no) | 1997-01-10 |
MX9700245A (es) | 1997-05-31 |
BR9508395A (pt) | 1997-12-23 |
DE4424714A1 (de) | 1996-01-18 |
CO4410185A1 (es) | 1997-01-09 |
CN1152303A (zh) | 1997-06-18 |
KR970704674A (ko) | 1997-09-06 |
CZ8297A3 (en) | 1997-09-17 |
HUT76827A (en) | 1997-11-28 |
FI970095A0 (fi) | 1997-01-10 |
AU2736895A (en) | 1996-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1203764B1 (de) | Benzamidinderivate mit LTB4- antagonistischer Wirkung | |
DE60006280T2 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
AT363096B (de) | Verfahren zur herstellung von neuen phthalazinderivaten und deren salzen | |
DE2833140C2 (xx) | ||
DE2558501C2 (xx) | ||
WO1996002496A1 (de) | Neue chemische verbindung, ihre herstellung und ihre verwendung als arzneistoff | |
EP0770059B1 (de) | Substituierte benzamidine, ihre herstellung und verwendung als arzneimittel | |
EP1015421B1 (de) | Neue phenylamidinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
WO2008061456A1 (fr) | Composé folacine-metformine et sa production | |
DE2713389A1 (de) | Neuartige xanthinverbindungen und dieselben enthaltende pharmazeutische zubereitung | |
DE60005517T2 (de) | Kaliumkanal-blockierende mittel | |
EP0557879A1 (de) | 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung | |
EP0096279B1 (de) | N-(2-Methoxyethyl)-noroxymorphon, dessen Säureadditionssalze, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung | |
EP0171645A1 (de) | Neue 2H-1-Benzopyran-2-on-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten | |
EP0980351B1 (de) | Benzylaminderivate und phenylethylaminderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
EP0000693B1 (de) | Aminophenoxymethyl-2-morpholinderivate, ihre Herstellung und sie enthaltende Arzneimittel | |
WO2002034715A1 (de) | Benzamidin-derivate mit einer sulfat-gruppe als ltb4-antagonisten | |
EP0557877B1 (de) | Lösliche Salze von 4-Amino-2-(4,4-dimethyl-imidazolidin-2-on-1-yl)-pyrimidin-5 -carbonsäure- N-methyl-N-(3-trifluormethyl-phenyl)- amid, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und Ausgangsprodukte | |
EP1222162B1 (de) | Neuer ltb4-antagonist, verfahren zu dessen herstellung und dessen verwendung als arzneimittel | |
CH633962A5 (en) | Pharmaceutical preparations which contain pteridine compounds | |
DD210266A5 (de) | Verfahren zur herstellung von 3-(ureidocyclohexylamino)-propan-1,2-diolderivaten | |
EP0590558B1 (de) | Arzneimittel enthaltend 1,5,6,7-Tetrahydro-4H-indazol-4-one, neue 1,5,6,7-Tetrahydro-4H-indazol-4-one und verfahren zu ihrer Herstellung | |
DE2525164C2 (de) | m-Phenylendioxamsäurediester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen | |
DE2827454A1 (de) | 4-homoisotwistanderivate, verfahren zu ihrer herstellung, verwendung derselben und diese enthaltende arzneimittel | |
DE1958212A1 (de) | Neue substituierte N-Cycloalkyl-arylamino-imidazoline-(2) und Verfahren zu deren Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970213 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 970213;LV PAYMENT 970213;SI PAYMENT 970213 |
|
17Q | First examination report despatched |
Effective date: 19971204 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BOEHRINGER INGELHEIM PHARMA KG |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19980728 |